0000000001085611

AUTHOR

Gianluigi Vendemiale

showing 8 related works from this author

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

Mitochondrial function in liver disease.

2006

Oxidative stress is involved in the pathogenesis and progression of different liver diseases, such as alcoholic liver disease and biliary cirrhosis. The increased mitochondrial production of O2(-) at complexes I and III, and consequently of H2O2 and other reactive oxygen species (ROS), triggered by NADH overproduction seems the major cause of mitochondrial and cellular oxidative stress and damage in chronic alcoholism. The mitochondrial oxidative stress renders hepatocytes susceptible to ethanol- or acetaldehyde-induced mitochondrial membrane permeability transition (MMPT) and apoptosis. Nitrosative stress contributes to cell death by peroxynitrite formation. The expression of the death rec…

Alcoholic liver diseaseProgrammed cell deathBiliary cirrhosisPopulationApoptosisMitochondria LiverMitochondrionmedicine.disease_causechemistry.chemical_compoundmedicineCardiolipinAnimalsHumanseducationLiver Diseases Alcoholicchemistry.chemical_classificationeducation.field_of_studyReactive oxygen speciesLiver Cirrhosis BiliaryLiver Diseasesmedicine.diseaseNADCell biologyRatsOxidative StresschemistryHepatocytesOxidative stressFrontiers in bioscience : a journal and virtual library
researchProduct

Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia…

2008

Background: The mechanisms of progression from fatty liver to steatohepatitis and cirrhosis are not well elucidated. Mitochondrial dysfunction represents a key factor in the progression of non-alcoholic steatohepatitis (NASH) as mitochondria are the main cellular site of fatty acid oxidation, ATP synthesis and reactive oxygen species (ROS) production. Aims: (1) To evaluate the role of the uncoupling protein 2 in controlling mitochondrial proton leak and ROS production in NASH rats and humans; and (2) to assess the acute liver damage induced by ischaemia–reperfusion in rats with NASH. Methods: Mitochondria were extracted from the livers of NASH humans and rats fed a methionine and choline de…

AdultMaleMitochondrial ROSmedicine.medical_specialtyMitochondria LiverMitochondrionBiologymedicine.disease_causeIon ChannelsMitochondrial ProteinsAdenosine TriphosphateInternal medicinemedicineAnimalsHumansUncoupling proteinUncoupling Protein 2Rats WistarBeta oxidationAdenosine TriphosphatasesMembrane Potential MitochondrialAldehydesFatty liverGastroenterologyMiddle Agedmedicine.diseaseRatsFatty LiverOxidative StressEndocrinologyMitochondrial respiratory chainLiverBiochemistryReperfusion InjuryAcute DiseaseDisease ProgressionFemaleSteatohepatitisReactive Oxygen SpeciesOxidative stressGut
researchProduct

Heart failure and chronic kidney disease in a registry of internal medicine wards

2014

Background: The aim of the present study was to evaluate the association between heart failure (HF) and chronic kidney disease (CKD) in tertiary care centers using the clinical records of patients enrolled in internal medicine departments.Patients and methods: We used the clinical records of 1380 elderly patients to identify patients with a history of HF and CKD using admission ICD codes and glomerular filtration rate (GFR) formulas. Magnitude and strength of such associations were investigated by univariable and multivariable analysis.Results: Of the 1380 patients enrolled, 27.9% had HF (age 80 ± 7, BMI 27 ± 6 kg/m2) and 17.4% CKD (age 81 ± 7, BMI 26.8 ± 6 kg/m2). Both groups were signific…

medicine.medical_specialtyChronic kidney disease; Elderly; Heart failure; REPOSI; Gerontology; Geriatrics and GerontologyHeart failure; Elderly; Chronic kidney disease; REPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Gerontology; Geriatrics and GerontologyChronic kidney disease; Elderly; Heart failure; REPOSIRenal functionHeart failure; chronic kidney disease; elderly; registry; REPOSIHeart failureregistryTertiary careSleep Apnea SyndromeElderlySleep Apnea SyndromesInternal medicineChronic kidney diseaseEpidemiologymedicineHumansNoninvasive Ventilationbusiness.industryREPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Geriatrics and Gerontology; Gerontologymedicine.diseaseHeart failureHeart failure Elderly Chronic kidney disease REPOSIIcd codesGeriatrics and GerontologybusinessClinical recordBody mass indexGerontologyKidney diseaseHuman
researchProduct

Targeting Mitochondria: A New Promising Approach for the Treatment of Liver Diseases

2010

Mitochondrial dysfunction acts as a common pathogenetic mechanism in several acute and chronic liver diseases, such as Alcoholic and Non-Alcoholic Fatty Liver Disease (NAFLD), drug-induced steatohepatitis, viral hepatitis, biliary cirrhosis, hepatocellular carcinoma, ischemia/reperfusion injury and transplant rejection. In particular mitochondrial uncoupling has been recently identified to play a determinant role in the pathogenesis of liver diseases by causing decrease of mitochondrial proton motive force and ATP depletion. Damaged mitochondria present defects in lipid homeostasis, bioenergetics impairment and overproduction of Reactive Oxygen Species (ROS), leading to lipid accumulation a…

Programmed cell deathMitochondrionBiologymedicine.disease_causeBiochemistryLiver diseaseDrug Delivery SystemsDrug DiscoverymedicineAnimalsHumansPharmacologychemistry.chemical_classificationReactive oxygen speciesCell DeathLiver DiseasesOrganic ChemistryFatty livermedicine.diseaseMitochondriaOxidative StressBiochemistrychemistryCancer researchMolecular MedicineSteatohepatitisReactive Oxygen SpeciesReperfusion injuryOxidative stressCurrent Medicinal Chemistry
researchProduct

Mitochondrial involvement in non-alcoholic steatohepatitis

2007

Non-alcoholic steatohepatitis (NASH) is an increasing recognized condition that may progress to end-stage liver disease. There are consistent evidences that mitochondrial dysfunction plays a central role in NASH whatever its origin. Mitochondria are the key controller of fatty acids removal and this is part of an intensive gene program that modifies hepatocytes to counteract the excessive fat storage. Mitochondrial dysfunction participates at different levels in NASH pathogenesis since it impairs fatty liver homeostasis and induces overproduction of ROS that in turn trigger lipid peroxidation, cytokines release and cell death. In this review we briefly recall the role of mitochondria in fat…

Mitochondrial DNAmedicine.medical_specialtyClinical BiochemistryBiologyMitochondrionModels BiologicalBiochemistryEnergy homeostasisAdenosine TriphosphateInternal medicinemedicineAnimalsHumansMolecular BiologyFatty liverGeneral MedicineTFAMLipid Metabolismmedicine.diseaseMitochondriaFatty LiverEndocrinologyMitochondrial respiratory chainMolecular MedicineSteatohepatitisSteatosisReactive Oxygen SpeciesMolecular Aspects of Medicine
researchProduct

Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress

2004

Ursodeoxycholic acid (UDCA) improves clinical and biochemical indices in primary biliary cirrhosis and prolongs survival free of liver transplantation. Recently, it was suggested that the cytoprotective mechanisms of UDCA may be mediated by protection against oxidative stress, which is involved in the development of cirrhosis induced by chronic cholestasis. The aims of the current study were 1) to identify the mechanisms involved in glutathione depletion, oxidative stress, and mitochondrial impairment during biliary cirrhosis induced by chronic cholestasis in rats; and 2) to determine the mechanisms associated with the protective effects of UDCA against secondary biliary cirrhosis. The find…

Malemedicine.medical_specialtyCirrhosisCardiolipinsGlutamate-Cysteine LigaseBiliary cirrhosisPopulationBiologymedicine.disease_causeMembrane Potentialschemistry.chemical_compoundPrimary biliary cirrhosisInternal medicinemedicineCardiolipinAnimalsRats Wistareducationeducation.field_of_studyCholestasisHepatologyLiver Cirrhosis BiliaryUrsodeoxycholic AcidCystathionine gamma-LyaseGlutathionemedicine.diseaseGlutathioneUrsodeoxycholic acidMitochondriaPeroxidesRatsOxidative StressEndocrinologyLiverchemistryChronic DiseaseHepatocytesOxidation-ReductionOxidative stressmedicine.drugHepatology
researchProduct

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

2016

Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths. Methods: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed. Results: Among 2535 patients, 558 (22.0 %) were discharged with a diagnos…

Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Cardiology and Cardiovascular MedicineMaleRegistrieTime Factorsantithrombotic therapy; atrial fibrillation; elderly; guidelines; outcomesAtrial fibrillation (AF)Practice PatternsKaplan-Meier Estimate030204 cardiovascular system & hematologyGuidelineoutcomesCoronary artery disease0302 clinical medicineElderlyRisk FactorsAtrial FibrillationAntithrombotic80 and overAge Factor030212 general & internal medicineRegistriesguidelinesAntithrombotic therapy Atrial fibrillation Elderly Guidelines OutcomesPractice Patterns Physicians'OutcomeAged 80 and overFibrinolytic AgentAge FactorsAtrial fibrillationGeneral MedicineTreatment OutcomeItalyAtrial fibrillation (AF) thromboembolism antithrombotic prophylaxisPractice Guidelines as TopicCardiologyFemaleGuideline AdherenceCardiology and Cardiovascular MedicineHumanAntithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Age Factors; Aged; Aged 80 and over; Atrial Fibrillation; Chi-Square Distribution; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Practice Patterns Physicians'; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Practice Guidelines as Topic; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyLogistic ModelTime FactorSocio-culturaleLower riskRisk Assessment03 medical and health sciencesFibrinolytic AgentsInternal medicineThromboembolismmedicineHumansProportional Hazards ModelsAgedAntithrombotic therapyPhysicians'Chi-Square Distributionbusiness.industryProportional hazards modelRisk FactorSettore MED/09 - MEDICINA INTERNAGuidelinethromboembolismmedicine.diseaseAtrial fibrillationLogistic ModelsProportional Hazards Modelantithrombotic prophylaxisbusinessChi-squared distributionFibrinolytic agent
researchProduct